{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:46:05Z","timestamp":1784292365496,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jpba.2022.115219","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T01:59:24Z","timestamp":1672451964000},"page":"115219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model compounds"],"prefix":"10.1016","volume":"225","author":[{"given":"Juha","family":"Jyrk\u00e4s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Lassila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Tolonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2022.115219_bib1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.copbio.2006.10.002","article-title":"Therapeutic peptides: technological advances driving peptides into development","volume":"17","author":"Sato","year":"2006","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jpba.2022.115219_bib2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: Current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jpba.2022.115219_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The Future of Peptide-based Drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.jpba.2022.115219_bib4","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.ddtec.2011.11.006","article-title":"Overcoming poor permeability: translating permeation enhancers for oral peptide delivery","volume":"9","author":"Maher","year":"2012","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.jpba.2022.115219_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic Approaches to Optimizing Peptide ADME Properties","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2022.115219_bib6","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1080\/00498254.2021.2020377","article-title":"Meeting report: 3rd workshop of the peptide ADME discussion group","volume":"51","author":"Sonesson","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpba.2022.115219_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178943","article-title":"Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum","volume":"12","author":"B\u00f6ttger","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2022.115219_bib8","doi-asserted-by":"crossref","unstructured":"A. Bernkop-Schn\u00fcrch, T. Schmitz, Presystemic Metabolism of Orally Administered Peptide Drugs and Strategies to Overcome It, 2007.","DOI":"10.2174\/138920007780866834"},{"key":"10.1016\/j.jpba.2022.115219_bib9","unstructured":"Lupron package insert, (2014). \u3008https:\/\/www.accessdata.fda.gov\/%0Adrugsatfda_docs\/label\/2014\/020517s036_019732s041lbl.pdf\u3009."},{"key":"10.1016\/j.jpba.2022.115219_bib10","unstructured":"Cetroride package insert, (2019). \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cetrotide-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2022.115219_bib11","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/S0021-9258(17)42019-9","article-title":"Mechanism of Cyclosporin A Biosynthesis","volume":"269","author":"Dittmann","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2022.115219_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00003088-198611020-00002","article-title":"Clinical Pharmacokinetics of Cyclosporin","volume":"11","author":"Ptachinski","year":"1986","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.jpba.2022.115219_bib13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/clpt.1988.87","article-title":"Cyclosporin metabolism in human liver: Identification of a cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs","volume":"43","author":"Kronbach","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2022.115219_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113921","article-title":"Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds","volume":"196","author":"Jyrk\u00e4s","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115219_bib15","first-page":"1","article-title":"Trypan Blue Exclusion Test of Cell Viability","volume":"111","author":"Strober","year":"2001","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.jpba.2022.115219_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.pharmtox.46.120604.141043","article-title":"Human Flavin-Containing Monooxygenases","volume":"46","author":"Cashman","year":"2006","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jpba.2022.115219_bib17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00204-008-0332-8","article-title":"Inhibition and induction of human cytochrome P450 enzymes: Current status","volume":"82","author":"Pelkonen","year":"2008","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.jpba.2022.115219_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23102615","article-title":"Amide bond activation of biological molecules","volume":"23","author":"Mahesh","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2022.115219_bib19","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s10989-021-10177-0","article-title":"A Review on the Metabolism of 25 Peptide Drugs","volume":"27","author":"Brian Chia","year":"2021","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.jpba.2022.115219_bib20","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jms.1416","article-title":"In vivo evaluation and in vitro metabolism of leuprolide in mice - mass spectrometry-based biomarker measurement for efficacy and toxicity","volume":"43","author":"Sofianos","year":"2008","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2022.115219_bib21","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/mp500809f","article-title":"Toward oral delivery of biopharmaceuticals: An assessment of the gastrointestinal stability of 17 peptide drugs","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jpba.2022.115219_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0378-5173(94)00407-V","article-title":"Intestinal permeation and metabolism of a model peptide (leuprolide) and mechanisms of permeation enhancement by non-ionic surfactants","volume":"120","author":"Imanidis","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2022.115219_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0168-3659(96)01586-6","article-title":"The challenge of proteolysis enzymes in intestinal peptide delivery","volume":"46","author":"Langguth","year":"1997","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jpba.2022.115219_bib24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijpharm.2004.03.031","article-title":"Transport of leuprolide across rat intestine, rabbit intestine and Caco-2 cell monolayer","volume":"278","author":"Guo","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2022.115219_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00227927","article-title":"Proline specific endo- and exopeptidases","volume":"30","author":"Walter","year":"1980","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jpba.2022.115219_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0090-9556(24)14996-3","article-title":"Disposition and metabolism of cetrorelix, a potent luteinizing hormone- releasing hormone antagonist, in rats and dogs","volume":"28","author":"Schwahn","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2022.115219_bib27","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.1021\/acsomega.9b00603","article-title":"Solubility Studies of Cyclosporine Using Ionic Liquids","volume":"4","author":"Berton","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.jpba.2022.115219_bib28","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.bcp.2004.07.012","article-title":"In vitro metabolism of cyclosporine A by human kidney CYP3A5","volume":"68","author":"Dai","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2022.115219_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/004982599238777","article-title":"Species differences in the hepatic and intestinal metabolism of cyclosporine","volume":"29","author":"Whalen","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpba.2022.115219_bib30","doi-asserted-by":"crossref","unstructured":"K.M. Knights, A. Rowland, J.O. Miners, K. Knights, Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT), (2013). https:\/\/doi.org\/10.1111\/bcp.12086.","DOI":"10.1111\/bcp.12086"},{"key":"10.1016\/j.jpba.2022.115219_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2015.06.018","article-title":"Stability of peptide drugs in the colon","volume":"78","author":"Wang","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2022.115219_bib32","doi-asserted-by":"crossref","first-page":"13131","DOI":"10.1021\/acs.jmedchem.1c00580","article-title":"Cyclosporin Structure and Permeability: From A to Z and beyond","volume":"64","author":"Corbett","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2022.115219_bib33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.addr.2016.06.002","article-title":"Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: Mechanisms and challenges","volume":"111","author":"Komin","year":"2017","journal-title":"Adv. Drug Deliv. Rev. 110\u2013"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522006409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522006409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:26:02Z","timestamp":1760001962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522006409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":33,"alternative-id":["S0731708522006409"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115219","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model compounds","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115219"}}